INTRODUCTION {#sec1}
============

*Chlamydia trachomatis* is a Gram-negative, obligate intracellular pathogen that can lead to a broad spectrum of clinical diseases in human populations. It is known to cause a significant burden of preventable blindness in third world countries. *Chlamydia trachomatis* is also known as the most common bacterial sexually transmitted infection worldwide (Newman *et al.*[@bib46]). With a total of over 130 million new cases per year worldwide in 2015, *C. trachomatis* infections represent a major problem worldwide. Latest trends furthermore seem to indicate that this number is likely to increase (WHO [@bib63]). Urogenital infections with *C*. *trachomatis* have been associated with a wide range of genitourinary conditions including cervicitis and salpingitis in women as well as epididymitis and urethritis in men. Infection with the pathogen is however often asymptomatic and hence frequently remains undiagnosed, leading to an array of severe long-term consequences (Haggerty *et al.*[@bib26]). Studies indicate that chlamydial infections can lead to severe impairments such as pelvic inflammatory disease, tubal damage and ultimately tubal factor infertility in women if they are not treated in a timely and adequate fashion (den Hartog, Morré and Land [@bib10]; Haggerty *et al.*[@bib26]). Additionally, infections with *C. trachomatis* can severely impact the reproductive health of women, causing severe conditions such as ectopic pregnancies, repeated and spontaneous abortions and stillbirths(Tiller [@bib60]; Baud and Greub [@bib5]). These features render timely identification and reliable diagnosis of *C. trachomatis* an issue of public health importance, as the disease can effectively be treated using antibiotics. This is particularly true in developing countries, where infectious disease already significantly burdens the populations and the healthcare systems (Gangolli, Duggal and Shukla [@bib17]; John *et al.*[@bib31]). The asymptomatic nature of the disease also requires evidence-based guidelines for the implementation of population-wide screening programs. In fact, studies have claimed that, due to the low prevalence of Chlamydia at the population level, screening in the general population may not be cost-effective (Low *et al.*[@bib38]). The identification of high-risk groups or chlamydial infections is however a public health issue (Althaus *et al.*[@bib2]). This aspect is particularly significant for low and middle-income countries, where healthcare resources and budgets are limited (CDC and World Bank [@bib7]).

With a total population of approximately 1.2 billion inhabitants, India is after China the second most populous country in the world (Perianayagam and Goli [@bib50]). It is similarly known to be home to one of the greatest burden of Infectious diseases in the world (John *et al.*[@bib31]). There is however a paucity of data and a lack of overview concerning the burden of *C. trachomatis* infections in India. Insights regarding the strategies for diagnosis and management of *C. trachomatis* in healthcare settings are also limited (Malhotra *et al.*[@bib41]). As a result of the varying levels of specificity and sensitivity of the diagnostic tools utilized in the clinical settings, the choice of method is of primordial importance (Chernesky [@bib9]).

The aim of this paper is to systematically review the available scientific literature to investigate the urogenital *C. trachomatis* burden in India, across different regions and patient groups. The initial scope of this review is to provide an overview of the prevalence of the disease among the different patient groups. Additionally, the techniques used to identify *C. trachomatis* in patients need to be assessed, to lead the way for formulation of future best practices and potential evidence-based guidelines for diagnosis and management of *C. trachomatis* across the Indian subcontinent. Finally, in light of the significant impact of *C. trachomatis* on the female reproductive tract, and the importance of maternal and child health in India, the disease\'s contributions to the national burden of reproductive health needs to be clarified (Inhorn and Bharadwaj [@bib29]; Ganguly and Unisa [@bib18]; Mahesh [@bib39]) in order to aid policy decisions.

METHODS {#sec2}
=======

Peer-reviewed articles included in this review were obtained from the major databases namely PubMed and Embase using the search headlines '*Chlamydia trachomatis'* and 'India'. Additionally, Google Scholar was screened with the same search criteria to include non-indexed articles and 'gray' literature (Mahood, Van Eerd and Irvin [@bib40]). Lastly, all the references and work cited by the articles included in this review were screened to identify further articles to be included. The above databases were screened for available data from August 2015 until December 2015.

In light of the previously mentioned lack of consistent data originating from the Indian settings, the scope of the literature search was designed to include all the patient groups that are at a higher risk of infection or subsequent sequelae when considering *C. trachomatis.* Taking into account the exploratory nature of the review, the authors screened all articles based on the type of patient population, the diagnostic method utilized to test for a urogenital *C. trachomatis* and the geographical location of the study. All of the studies that suited the scope of the review were included for further analysis based on the abstract and reviewed by at least two of the authors and checked for duplicates. The included articles were then scrutinized individually in their full-text versions. The final inclusion of discordant studies was then discussed with the authors.

If the data screened did not feature population testing, described laboratory techniques in relation with *C. trachomatis* detection or Chlamydia typing of established positive samples, they were excluded from this review. Additionally, all duplicates were excluded.

RESULTS {#sec3}
=======

The combined literature search yielded a total of 27 unique articles; the details of the inclusion are summarized in Fig. [1](#fig1){ref-type="fig"}.

![Sources of included articles.](ftx055fig1){#fig1}

The literature search succeeded in unveiling scientific studies originating from a wide range of geographical locations. However, the city of New Delhi was over-represented, as over a third of all the included studies (11/27 = 40%) could be traced back to this location. Similarly, three studies originated from the city of Mumbai and three others from the city of Chennai, respectively. Additionally, it should be noted that most of the studies originated from urban settings, as only two studies were conducted in rural settings (2/27 = 7%). The locations of the different studies included are summarized in Fig. [2](#fig2){ref-type="fig"}.

![Geographical locations of studies (obtained with Google mymaps).](ftx055fig2){#fig2}

The differences in the testing methods used to diagnose *Chlamydia trachomatis* and the differences in patient populations enclosed in this review render a meta-analysis of the data difficult. Some distinct patient groups could however be consistently identified and grouped together for analysis. A total of four patient groups could be identified as listed below (see Table [1](#tbl1){ref-type="table"} for details): Symptomatic patients presenting in healthcare settings: 13 identified studies.Infertile and subfertile women: seven identified studies.Pregnant women: two identified studies and four control groups.Asymptomatic population groups: three studies and one control group included

###### 

The articles are color-coded based on the patient groups they feature: Group 1 (green): symptomatic women; Group 2 (blue): infertile and subfertile women; Group 3 (red): pregnant women; Group 4 (white): asymptomatic population groups.

  ---------------------
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Symptomatic patients presenting at the gynecology outpatient department (OPD) {#sec3-1}
-----------------------------------------------------------------------------

The first patient population was the most represented in the review with a total of 13 studies identified. The details of the studies are featured in Table [2](#tbl2){ref-type="table"}. The prevalence of *C. trachomatis* among the studies ranged from 10% in the study by Sood *et al.* ([@bib59]) to 50% in the study by Gopalkrishna *et al.* ([@bib23]) using polymerase chain reaction (PCR), both in New Delhi (Gopalkrishna *et al.*[@bib23]; Sood *et al.*[@bib59]). However, another study from Chennai by Pushpa Innocent ([@bib51]) using ELISA reported a prevalence of 75%. The predominance of studies from New Delhi could also be observed in this group. Eight of the studies conducted on symptomatic patients were in fact conducted in New Delhi.

###### 

*Chlamydia trachomatis* prevalence among symptomatic patients (results given for PCR or most sensitive technique).

  Authors                               Location    Testing              Cohort size   Prevalence
  ------------------------------------- ----------- -------------------- ------------- -----------------------
  Mania-Pramanik *et al.* ([@bib44])    Mumbai      PCR                  896           12%
  Sood *et al.* ([@bib59])              New Delhi   DFA, PCR             97            10%
  Gita *et al.* ([@bib21])              New Delhi   DFA, PCR Culture,    2466          15% (DFA)/13.2% (PCR)
  Patel *et al.* ([@bib48])             New Delhi   PCR                  593           23%
  Pushpa Innocent ([@bib51])            Chennai     IgG ELISA            280           60%/75% (two cohorts)
  Dwibedi *et al.* ([@bib13])           Cuttack     PCR                  108           7.0%
  Gupta, Salhan and Mittal ([@bib25])   New Delhi   IgG ELISA            355           30%
  Malhotra *et al.* ([@bib40a])         New Delhi   DFA, IgG IgM ELISA   276           19%
  Vinita *et al.* ([@bib62])            Lucknow     PCR                  100           14%
  Singh *et al.* ([@bib58])             New Delhi   PCR                  280           28%
  George *et al.* ([@bib19])            Chennai     Culture and PCR      143           32%
  Singh *et al.* ([@bib57])             New Delhi   DFA, PCR             350           43%
  Gopalkrishna *et al.* ([@bib23])      New Delhi   IgG ELISA, PCR       50            50%

A similar study testing on men attending the STD clinic in Mumbai was also identified. The authors however did not specify patient details. The study reported 2.2% *C. trachomatis* prevalence using first-void urine (FVU) PCR (Lindan *et al.*[@bib37]).

Infertile and subfertile women {#sec3-2}
------------------------------

Female patients (repeatedly) infected with *C. trachomatis* are known to be at an elevated risk for late complications,i.e. tubal factor infertility (den Hartog, Morré and Land [@bib10]). Seven studies conducted among infertile and subfertile women were included. The results are summarized in Table [3](#tbl3){ref-type="table"}. The prevalence ranged from 9% in Indore in central region of India to 68% in a study performed in Amritsar, making use of enzyme immunoassay (Sharma, Aggarwal and Arora [@bib56]; Bajpai, Ganesh and Neelesh [@bib3]). A further study from Kolkata in the eastern region of India reported an even lower prevalence using PCR (2.5%) (Ghosh *et al.*[@bib20]). The same study nonetheless reported a seroprevalence of the pathogen of 15% while testing with ELISA (Ghosh *et al.*[@bib20]).

###### 

Prevalence among infertile and subfertile women (results given for PCR or most sensitive technique).

  Authors                                 Location    Testing              Cohort size   Prevalence
  --------------------------------------- ----------- -------------------- ------------- -------------------
  Ghosh *et al.* ([@bib20])               Kolkata     IgG ELISA, PCR       50            2.5%PCR 15% ELISA
  Mohan and Borthakur ([@bib45])          Guwahati    IgG ELISA            40            25%
  Bajpai, Ganesh and Neelesh ([@bib3])    Indore      IgG ELISA            111           9%
  Dhawan *et al.* ([@bib12])              New Delhi   PCR,DFA, EIA         200           13.5%
  Malik *et al.* ([@bib43])               Aligarh     IgG ELISA            20            55%
  Malik *et al.* ([@bib42])               Aligarh     Culture, IgG ELISA   110           28.1%
  Sharma, Aggarwal and Arora ([@bib56])   Amritsar    IgG EIA              50            68%

Pregnant women {#sec3-3}
--------------

The third group of interest is pregnant women. Two studies were identified where testing was conducted in pregnant women. Pregnant women were also used as a control group in four previously mentioned studies (Sharma, Aggarwal and Arora [@bib56]; Malik *et al.*[@bib42], [@bib43]; Ghosh *et al.*[@bib20]). All results are summarized in Table [4](#tbl4){ref-type="table"}. The reported prevalence of *C. trachomatis* in this group for studies reporting the use of PCR ranged from 0.1% in Vellore, South India, to 2.5% in the study by Ghosh *et al.* in Kolkata, East India (Vidwan *et al.*[@bib61]; Ghosh *et al.*[@bib20]). The prevalence range is even greater in the studies utilizing ELISA tests. These results range from 3.3% in Aligarh reported by Malik *et al.* ([@bib42]) to 18.6% in the study by Paul *et al.* ([@bib49]). The results featured in this group also display higher prevalence in the studies utilizing serology-based testing.

###### 

*Chlamydia trachomatis* prevalence among pregnant women (results given for PCR or most sensitive technique).

  Authors                                 Location    Testing              Cohort size   Prevalence
  --------------------------------------- ----------- -------------------- ------------- ------------
  Ghosh *et al.* ([@bib20])               Kolkata     ELISA, PCR           50            2.5%
  Vidwan *et al.* ([@bib61])              Vellore     PCR                  1198          0.1%
  Malik *et al.* ([@bib43])               Aligarh     IgG ELISA, culture   30            5.5%
  Malik *et al.* ([@bib42])               Aligarh     IgG ELISA, culture   30            3.3%
  Sharma, Aggarwal and Arora ([@bib56])   Amritsar    IgG EIA              50            10%
  Paul *et al.* ([@bib49])                New Delhi   Enzyme immunoassay   94 and 172    17%/18.6%

Asymptomatic population groups {#sec3-4}
------------------------------

Data from studies performing testing at the population level could only be found in three studies and one control group. The population screening group is hence the least represented group, the results and prevalence of the study are summarized in Table [5](#tbl5){ref-type="table"}. The populations screened in this patient group present with major differences in both sample size, origin and prevalence of *C. trachomatis*. The lowest prevalence (0.9%) was observed by Detels *et al.* among shop owners and commercial sex workers in Chennai, while the highest prevalence (24.5%) was reported for residents of slum areas in New Delhi by Singh *et al.* ([@bib57]). Both the aforementioned results were provided using PCR testing.

###### 

Prevalence of *Chlamydia trachomatis* in population screening (results given for PCR or most sensible technique).

  Authors                                        Location                                             Testing        Cohort size                Prevalence
  ---------------------------------------------- ---------------------------------------------------- -------------- -------------------------- ------------
  Detels *et al.* ([@bib11])                     Chennai                                              PCR            3513 (males and females    0.9%
  Savitha, Madhavan and Vinoth Raja ([@bib55])   Tanjore district, Tamil Nadu                         Giemsa Stain   200 (females)              10.5%
  Joyee *et al.* ([@bib33])                      Tanjore, Ramnad and Dingidul districts, Tamil Nadu   PCR            1849 (males and females)   1.1%
  Singh *et al*. ([@bib57])                      New Delhi                                            PCR            53 (males and females)     24.5%

Testing and diagnostic methods {#sec3-5}
------------------------------

The methods used to diagnose the disease and identify the pathogen in clinical settings are of pivotal importance. In fact, *C. trachomatis* can be identified through different tests, all of which have different characteristics. Although PCR is currently the gold standard for the identification of the bacteria in human subjects, it however can also be identified through culture (Centers for Disease Control and Prevention [@bib8]; Lanjouw *et al.*[@bib36]). On the other hand, serology-based tests such as ELISA are only suitable for screening in subfertile women. Serology tests help to ascertain the presence of an immune response against the pathogen through the detection of specific antibodies. These antibodies highlight a previous infection which is particularly relevant in the case of *C. trachomatis* infections (Keltz, Gera and Moustakis [@bib35]). Previous infections may in fact be the cause of tubal pathologies which can be traced back as the cause of infertility. Table [6](#tbl6){ref-type="table"} summarizes the testing methods featured in the studies included in this review. It should be noted that many of the studies made use of more than one diagnostic test.

###### 

Diagnostic and tests in the studies included in the review**.**

  Testing method         Number of studies
  ---------------------- -------------------
  In-house PCR           14
  ELISA                  13
  Commercial PCR tests   5
  DFA                    4
  Culture/Giemsa stain   3

The most commonly reported test in the review was in-house PCR testing, which was performed in 14 studies. ELISA immunological testing was the second most common test, present in 13 studies.

Material for PCR testing {#sec3-6}
------------------------

Material for the conduction of (or sample for conducting the) PCR testing can be obtained from different parts of the body as well as different bodily fluids. Each of the products requires a specific sampling procedure which might be more or less invasive. The origin of the sampled material for PCR among the different studies is summarized below. It should be specified that some of the studies featured more than one PCR assays requiring different materials each.

It can be seen that the most commonly used biological material for the conduction of PCR assays were endocervical swabs. It can be seen that the most commonly used biological material for the conduction of PCR assays were endocervical swabs, As featured in Table [7](#tbl7){ref-type="table"}. This method of sampling was used in 11 studies. Other methods included FVU and urine sampling, which were conducted in three studies each. Vaginal samples were used in only two studies.

###### 

Origin of the material for PCR testing.

  Material for PCR testing   Number of studies
  -------------------------- -------------------
  Endocervical swabs         11
  Urine                      3
  FVU                        3
  Vaginal swabs              2

DISCUSSION {#sec4}
==========

This review provides the first overview on the *Chlamydia trachomatis* prevalence in the Indian subcontinent. Articles and studies on the subject could be traced back to various geographical regions of India, and the results could be classified into symptomatic women, infertile and subfertile women and asymptomatic population groups. All of them display varying values *of C. trachomatis* prevalence, which can be attributed to the different settings where testing was conducted, the different population characteristics, but most importantly the tools used to diagnose the pathogen. The findings of this constitute a first attempt at identifying existing discrepancies attributable to differences in population testing techniques and locations regarding the current situation surrounding *C. trachomatis* in India. In fact, in all patient groups investigated in this review, the prevalence results stemming from studies making use of serology-based testing such as ELISA were as expected higher when compared with the results of studies using PCR.

It was observed that, in patient groups 1 and 2, the prevalence reported using ELISA serology is higher than results obtained through PCR testing. This highlights that the seroprevalence is higher among symptomatic and infertile patients when compared to other groups. The presence of an immune response to the pathogen as supported by positive results of serological tests in fact suggests a past or chronic exposure to the pathogen (Horner *et al.*[@bib28]). The high seroprevalences as compared to PCR prevalences suggest that previous *Chlamydia trachomatis* infection is related to long term consequences. In fact, PCR detects bacterial DNA inside of the patient\'s genital tract, which suggests a current infection rather than a past one. This finding underscores the role played by *C. trachomatis* in chronic infections leading to adverse health outcomes, and particularly, infertility.

Lack of studies featuring male participants could also be observed in group 1. In fact, only one study could be identified, where testing was conducted among men. This study could furthermore not be included in the tables, as the patients tested were not listed as symptomatic, but as attendees of the STD clinic, who may be present only for information. The only testing group where accounts for both men and women could be obtained was the group regarding population screening. Huge variations in terms of sample sizes in this group however restrict the scope for extrapolation. In fact, great differences in sample sizes were reported from this group. The sample size of the featured testing group ranges from 53 participants featured in the control group by Singh *et al.* ([@bib57]) in New Delhi to 3513 in the study by Detels *et al.* ([@bib11]) performed in the south Indian city of Chennai. This represents a testing group almost 70 times bigger.

The prevalence of *C. trachomatis* across the Indian Territory appears to vary across geographical regions and patient groups. The results suggest that the prevalence rates of *C. trachomatis* may be influenced by a variety of factors. Aspects influencing the prevalence of *C. trachomatis* may be attributable to differences in sensibility and specificity of testing, varied cultural backgrounds as well as healthcare practices and health-related beliefs. Additionally, the performance of local, state-run healthcare delivery systems varies greatly between the different states (Goli *et al.*[@bib22]). Moreover, research in different settings has highlighted the role of host genetic markers in the development of symptoms and consequences related to pathogens such as *C. trachomatis*. Genetic and genomic differences present within the different ethnicities that inhabit the Indian subcontinent could lead to varying prevalence of *C. trachomatis*. Furthermore, it should be stated that, despite the various represented patient groups included in this review, only three individual studies featured male patient groups. It should be furthermore stated that the only patient group where only men were represented was part of the asymptomatic population groups category. This limited data representing the male populations not only questions the completeness of the picture regarding the prevalence of *C. trachomatis* in the population but also raises the question of public health relevance associated with an undetected reservoir of infections, which could be held accountable for propagation of the disease. In addition, there are no mentions of contact tracing and partner testing in the different studies. Nonetheless, the data regarding prevalence featured in this article, with the exception of some very high prevalence numbers, match to some extent the prevalence data from European countries, when considering similar patient groups (ECDC [@bib14]; Redmond *et al.*[@bib53]). Additionally, and in a similar fashion compared with the Indian scenario, data from neighboring countries in similar situations and geographical locations are scarce. Some studies from Sri Lanka and Bangladesh nonetheless seem to suggest similar results across comparable patient groups. A study from the Colombo district in Sri Lanka in fact highlighted a *C. trachomatis* prevalence of 8.3% using PCR amid women attending the STI clinics (Kamani Mangalika *et al.*[@bib34]). In another study from Bangladesh, a prevalence rate of 23% from sexually active women was found using in-house PCR (Hoque *et al.*[@bib27]). The results from these studies support the range of prevalence, which was observed in similar groups in India. These results support the idea that *C. trachomatis* is associated with a significant burden of disease on the Indian subcontinent, particularly among high-risk groups such as sex workers and patients at STI clinics.

An important factor that may render the Indian settings unique regarding testing and identification of *C. trachomatis* and other sexually transmittable diseases in the community is the cultural stigma. Stigma was briefly mentioned in the study by Dwibedi *et al.* ([@bib13]) as a significant factor hindering women for seeking assistance and medical care for STI-related symptoms. Although no work could be identified highlighting the stigma against *C. trachomatis*, there exists a body of evidence surrounding the stigma surrounding HIV/AIDS in India. Many articles in fact support the idea that stigma is a major factor, present at multiple levels which hinders proper and timely management of HIV/AIDS, and that impacts the daily life of people affected by the diseases (Bharat [@bib6]; Ekstrand *et al.*[@bib15], [@bib16]). It is hence plausible that many people in the community shy away from getting diagnosed and treated with a sexually transmitted infection, even in spite of the fact that treatments and cures may exist, like in the case of *C. trachomatis*. This is further supported by experience of co-authors (Indian researchers/medical doctors) in this paper. This highlights the need for additional research into psychosocial factors influencing the health-seeking behavior of Indian patients. Stigma might in fact cause many patients to renounce seeking care and hence expose themselves to long-term health impairments. The absence of acknowledgement of the role of stigma related to STIs may suggest that the issue is widely ignored.

Furthermore, there seems to be discrepancies between the internationally recognized gold standards for *C. trachomatis* detection in industrialized countries and the practices currently implemented in India. As a matter of fact, only slightly short of half of all the studies included in this review featured testing using PCR. Most the PCR tests were performed in-house, while only five studies featured commercially available and internationally acclaimed tests such as the Roche AMPLICOR assay. It should be stressed that, as per the co-authors' experience, due to the elevated prices of some of the commercial PCR assays, in-house PCR tests might represent a valuable alternative for identification of *C. trachomatis* in healthcare settings. More research is nonetheless necessitated to better understand the properties of such tests. The values of specificity and sensitivity of in-house PCR tests ought to be judged against internationally acclaimed tests to ensure appropriate diagnosis. Additionally, there would be a need for evidence-based guidelines regarding the conduction of in-house PCR for the detection of *C. trachomatis.* Research conducted in Indian settings has highlighted that in-house PCR testing displays highly satisfactory results when compared to the AMPLICOR assay (Sachdeva *et al.*[@bib54]). Research from Trinidad and Tobago has further highlighted the use of in-house PCR as a valuable option for settings where the availability of commercial testing kits is limited (Rampersad *et al.*[@bib52]). Further research from South America has highlighted that a set of well-defined in-house PCR primers can be used for the detection of *C. trachomatis*, showcasing high levels of sensitivity and specificity when compared to gold standard kits (Aguilera-Arreola *et al.*[@bib1]).

Furthermore, many of the articles referred to cell culture as the gold standard for the detection and diagnosis of *C. trachomatis* in India. These aspects might be associated with the resource intensity of PCR when compared to more affordable testing methods such as culture, direct fluorescence assay (DFA) or ELISA. PCR testing in fact necessitates a vast array of equipment and expertise and can hence only be performed in some facilities and by trained staff. Identification through culture or serology can conversely be performed in traditional laboratory settings which are present in clinics and primary health centers. This further supports the need for cost-effective diagnostic tools for detection in resource-limited settings such as in India. It should hence be stated that research is needed for the implementation of novel testing and diagnosis methods for *C. trachomatis* and other pathogens in resource-limited settings.

Another important point brought up by the review is the discrepancies in research methodology among the included studies. The control group included in some of the studies did not match with the study populations. This holds in the article by Singh *et al.* ([@bib57]) for instance. The study in fact compares female patients in healthcare settings to randomly selected inhabitants of the slums. This also holds for the lack of information regarding the inclusion of these populations. Additionally, in the two studies by Malik *et al.* ([@bib42], [@bib43]), both testing groups composed of infertile women were compared to control groups that were smaller in size. The population tested for *C. trachomatis* ought to be thorough and representative of their populations in order to provide sound information to policy makers. This is especially true in studies aiming at screening populations, as they may guide future screening schemes for sexually transmitted diseases. Overall, there should be a drive towards high-quality research designs, in order to facilitate policy implementations aimed at addressing the burden of *C. trachomatis* among the Indian population. In fact, there is a need for high-quality research to enable the development of evidence-based guidelines for the management of *C. trachomatis* in Indian healthcare settings. The current standard operating procedure regarding the diagnosis and management of sexually transmissible diseases are in fact hard to identify and appear to be incomplete. The current guidelines issued by the government of India indeed miss *C. trachomatis* as a potential cause of vaginal discharge, although it is one of the most common manifestation of *C. trachomatis* infection once it presents with symptoms (Government of India [@bib24]). There is thus a need for clarity at the policy level for the identification, screening, prevention and treatment of pathogens like *C. trachomatis*. In addition of the need for cost-effective and readily implementable testing solutions, there is a need for more research in the policy strata. There is in fact a need for an encompassing policy framework taking all the relevant variables into account in order to foster safe, effective and evidence-based management of *C. trachomatis* infections as well as the long-term consequences they may cause.

This paper touches upon the topic of female infertility in India. This topic remains vastly unexplored, although some accounts suggest that the burden might underreported in India (Jejeebhoy [@bib30]; Malhotra *et al.*[@bib41]). There has been an increase in the number of couples that make use of *in vitro* fertilization and other methods in order to conceive (Widge and Cleland [@bib64]). Experts have also argued that the issue is not properly addressed and is not sufficiently investigated in Indian settings (Pande [@bib47]). Results from national surveys suggest a rise in the number of infertile couples (Mahesh [@bib39]). These factors ought to draw more attention on the burden of infertility, of which *Chlamydia trachomatis* is a major cause alongside other diseases such as *N. Gonorrhea*. In fact, not only is the detection of the pathogen straightforward, but a timely management and treatment of the infection may lead to a full recovery and replenished reproductive health.

CONCLUSION {#sec5}
==========

This review is the first endeavor to systematically review the prevalence of *Chlamydia trachomatis* across India. The studies included for analysis differed greatly based on research methodology, patient populations and testing methods used to diagnose *C. trachomatis* highlighting a need for standardization and guidelines for the identification and diagnosis of *C. trachomatis* in India. The prevalence of the disease across states and patient groups has been shown to vary quite significantly, suggesting the influential role of a wide range of factors including diagnostic tools and perhaps the genetic makeup of the different populations on the Indian subcontinent. More research is needed to develop novel diagnosis tests which are cost-effective and which can be implemented in resource-limited settings such as India. This paper highlights in-house PCR as a technique yielding high levels of sensitivity and specificity for pathogen identification. Tools and techniques however ought to be streamlined. More research is also necessary to ascertain the role of *C. trachomatis* in primary and secondary infertility in India as well as in adverse pregnancy outcomes. Further research will also need to be conducted in order to identify population subgroups that are at a high risk for sexually transmitted diseases and, particularly, for *C. trachomatis*. Policies and guidelines defining the identification and management of *C. trachomatis* in India also ought to be updated to maximize patient outcomes.
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